Because this TP53 mutation is not only found in serous carcinoma and because it is found in 94% of the cases presenting an HER2 gene amplification, research on HER2 gene amplification should not be exclusively reserved for serous carcinomas, as currently recommended. The gene discussed is ERBB2; the disease is serous adenocarcinoma.